PT2656860T - Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro - Google Patents

Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro

Info

Publication number
PT2656860T
PT2656860T PT131574857T PT13157485T PT2656860T PT 2656860 T PT2656860 T PT 2656860T PT 131574857 T PT131574857 T PT 131574857T PT 13157485 T PT13157485 T PT 13157485T PT 2656860 T PT2656860 T PT 2656860T
Authority
PT
Portugal
Prior art keywords
radiotherapy
methods
cells during
cancer chemotherapy
during cancer
Prior art date
Application number
PT131574857T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of PT2656860T publication Critical patent/PT2656860T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT131574857T 2005-06-17 2006-06-19 Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro PT2656860T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69157105P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
PT2656860T true PT2656860T (pt) 2021-07-28

Family

ID=37570784

Family Applications (2)

Application Number Title Priority Date Filing Date
PT131574857T PT2656860T (pt) 2005-06-17 2006-06-19 Preparações vasoconstritoras tópicas e métodos para proteção de células durante a quimoterapia e a radioterapia do cancro
PT67734764T PT1890732T (pt) 2005-06-17 2006-06-19 Preparações vasoconstritoras tópicas e processos destinados a proteger as células durante quimioterapia e radioterapia anticancerosas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT67734764T PT1890732T (pt) 2005-06-17 2006-06-19 Preparações vasoconstritoras tópicas e processos destinados a proteger as células durante quimioterapia e radioterapia anticancerosas

Country Status (15)

Country Link
US (4) US8114914B2 (enExample)
EP (2) EP1890732B1 (enExample)
JP (4) JP5756250B2 (enExample)
CN (3) CN107496925A (enExample)
AU (1) AU2006261358B2 (enExample)
CA (1) CA2611496C (enExample)
DK (2) DK1890732T3 (enExample)
ES (2) ES2675228T3 (enExample)
HK (1) HK1245143A1 (enExample)
HU (2) HUE038177T2 (enExample)
IL (2) IL191869A (enExample)
PL (2) PL2656860T3 (enExample)
PT (2) PT2656860T (enExample)
TR (1) TR201809015T4 (enExample)
WO (1) WO2006138691A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
JP4990142B2 (ja) 2004-08-23 2012-08-01 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
AU2006261358B2 (en) 2005-06-17 2012-05-31 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
EP1937219B1 (en) 2005-09-14 2015-11-11 MannKind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8785396B2 (en) * 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
MX336361B (es) 2008-06-20 2015-12-03 Mannkind Corp Un metodo y un aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
TWI547487B (zh) 2009-06-12 2016-09-01 曼凱公司 具限定比表面積之二酮基哌微粒子
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
US20140343159A1 (en) * 2011-06-02 2014-11-20 Procertus Biopharm, Inc. Formulation of small adrenergic agonist salt forms in organic solvents
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
BR112017009980A2 (pt) * 2014-11-14 2018-02-14 Follea Int ?sistema e método para prevenção de alopecia?.
ES2904543T3 (es) 2015-06-11 2022-04-05 ReJoy Tratamiento de la disfunción sexual
WO2019014518A1 (en) * 2017-07-14 2019-01-17 Galderma Research And Development METHODS AND COMPOSITIONS FOR REDUCING ADVERSE EFFECTS OF CHEMOTHERAPEUTIC TREATMENTS
JP2020530494A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
EP3887351A4 (en) * 2018-11-27 2022-11-02 The Trustees of Columbia University in the City of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FERROPTOSE AND TREATING EXCITOTOXIC DISORDERS
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions
AU2022443966A1 (en) 2022-03-04 2024-08-22 Vasodynamics Limited Topical compositions and methods.
CN119313747B (zh) * 2024-12-17 2025-04-15 中国海洋大学三亚海洋研究院 一种鱼类表皮体色量化方法和装置

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2414918A (en) * 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles
US2774789A (en) * 1947-10-24 1956-12-18 Sterling Drug Inc 1-arterenol and its acid-addition salts and preparation thereof
US2919230A (en) * 1953-10-29 1959-12-29 Rohm & Haas Hydrophilic base therapeutic compositions comprising cation-exchange resin
BE555319A (enExample) * 1956-03-21 1900-01-01
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
US3134720A (en) * 1962-06-27 1964-05-26 Bristol Myers Co Medicated gels
US3574859A (en) * 1968-07-05 1971-04-13 Carl M Kosti Process for the treatment of hypertrophied gums
GB2122892B (en) * 1982-07-02 1986-01-29 Squibb & Sons Inc Nystantin pastille formulation
SE457055B (sv) 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
US4853216A (en) * 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5013716A (en) 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
US5374645A (en) * 1990-01-22 1994-12-20 Ciba-Geigy Corporation Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol
US5260292A (en) * 1991-03-05 1993-11-09 Marvin S. Towsend Topical treatment of acne with aminopenicillins
JPH04327533A (ja) 1991-04-23 1992-11-17 Lion Corp 抗アレルギー用粘膜局所投与剤
US5534242A (en) 1994-05-02 1996-07-09 Henry; Richard A. Lidocaine-vasoconstrictor aerosol preparation
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
NL9401183A (nl) 1994-07-19 1996-03-01 Nederland Ptt Modulator/demodulatorinrichting voor koppeling van een dataterminal met een zend/ontvanginrichting, alsmede werkwijzen voor het tot stand brengen van een dataverbinding tussen een eerste en een tweede modulator/demodulatorinrichting.
GB9422571D0 (en) 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
EP0946155B2 (en) 1996-12-23 2009-01-21 S.L.A. Pharma AG Pharmaceutical composition for treating fecal incontinence
GB2370989A (en) 2001-01-16 2002-07-17 Btg Int Ltd Piperine analogues for the treatment of skin conditions
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP2001131085A (ja) * 1999-08-25 2001-05-15 Saitama Daiichi Seiyaku Kk 経皮・経粘膜吸収用の医薬組成物
MXPA02008403A (es) * 2000-02-28 2004-09-27 Vectura Ltd Mejoras en o relacionadas con el suministro de farmacos por via oral.
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
EP1329217A4 (en) 2000-10-06 2007-04-04 Takeda Pharmaceutical Solid preparations
GB0028575D0 (en) * 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
EP1363602A4 (en) 2001-01-25 2006-01-11 Euro Celtique Sa LOCAL ANESTHESIA, AND METHOD OF USE
EP1997478B1 (en) 2001-02-15 2013-09-04 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US20040176359A1 (en) 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20020192273A1 (en) 2001-06-15 2002-12-19 Teri Buseman Therapeutic patch useful for the treatment of hemorrhoids
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
JP4544391B2 (ja) * 2001-12-28 2010-09-15 ライオン株式会社 眼科用組成物
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2005014524A2 (en) * 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
JP2007502839A (ja) 2003-08-21 2007-02-15 トランソラル ファーマシューティカルズ，インコーポレイティド 口腔粘膜を介して５−ｈｔアゴニストを運搬するための組成物及びその使用方法
US20070219253A1 (en) * 2003-09-17 2007-09-20 Gul Balwani Decongestant / antihistaminic / expectorant compositions
EP1737434A2 (en) 2004-04-13 2007-01-03 Alza Corporation Apparatus and method for transdermal delivery of fentanyl-based agents
AU2006261358B2 (en) * 2005-06-17 2012-05-31 Wisconsin Alumni Research Foundation Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy

Also Published As

Publication number Publication date
HUE054887T2 (hu) 2021-10-28
IL191869A0 (en) 2011-08-01
HK1245143A1 (zh) 2018-08-24
US8247457B2 (en) 2012-08-21
EP1890732B1 (en) 2018-03-28
WO2006138691A1 (en) 2006-12-28
CN103948927A (zh) 2014-07-30
EP1890732A1 (en) 2008-02-27
US20120316246A1 (en) 2012-12-13
CA2611496A1 (en) 2006-12-28
TR201809015T4 (tr) 2018-07-23
HUE038177T2 (hu) 2018-09-28
ES2880624T3 (es) 2021-11-25
US20110218223A1 (en) 2011-09-08
AU2006261358B2 (en) 2012-05-31
EP1890732A4 (en) 2010-07-07
CN103948927B (zh) 2017-11-07
ES2675228T3 (es) 2018-07-09
EP2656860A1 (en) 2013-10-30
DK1890732T3 (en) 2018-07-02
US8114914B2 (en) 2012-02-14
IL232904A (en) 2015-11-30
EP2656860B1 (en) 2021-05-05
JP2016155880A (ja) 2016-09-01
CA2611496C (en) 2015-07-28
US20160136113A1 (en) 2016-05-19
JP6348437B2 (ja) 2018-06-27
JP5756250B2 (ja) 2015-07-29
IL232904A0 (en) 2014-07-31
AU2006261358A1 (en) 2006-12-28
HK1200087A1 (en) 2015-07-31
CN107496925A (zh) 2017-12-22
JP6473103B2 (ja) 2019-02-20
PL2656860T3 (pl) 2021-11-08
IL191869A (en) 2014-06-30
US11197836B2 (en) 2021-12-14
CN101198362A (zh) 2008-06-11
JP2018203788A (ja) 2018-12-27
JP2008543876A (ja) 2008-12-04
CN101198362B (zh) 2014-03-12
US20070077219A1 (en) 2007-04-05
DK2656860T3 (da) 2021-07-26
PT1890732T (pt) 2018-07-02
JP2015098496A (ja) 2015-05-28
PL1890732T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
IL232904A (en) Blood Vessel Remedies and Cell Protection Methods for Chemotherapy and Cancer Therapy
WO2008054726A3 (en) Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
IL183789A0 (en) Methods and aparatus for providing ballistic protection
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
IL185463A0 (en) Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
MXPA02010866A (es) Composiciones y metodos para proteger celulas durante la quimioterapia y radioterapia contra el cancer.
AU2003258061A1 (en) Therapeutic inhibitionof protein kinases in cancer cells
GB0519405D0 (en) Cancer therapy prognosis and target
EP1718280A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2005954B8 (en) Kit for cancer therapy and pharmaceutical composition for cancer therapy
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP1773883A4 (en) PRODUCTION OF ANTICANCER ANTIBODIES USING MASKED CANCER CELLS AS IMMUNOGENS
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
WO2008013989A8 (en) Methods and compositions for identifying a cellular immune response against prostate cancer
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
AU2003271457A1 (en) Methods for detecting prostate cancer
AU2002319792A1 (en) Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
HK1122507A (en) Methods and compositions for treating prostate cancer
AU2007901628A0 (en) Methods and compositions for treating prostate cancer
GB0405258D0 (en) Selective chemotherapy of malignant cancer cells
GB0424624D0 (en) Selective chemotherapy of malignant cancer cells
HK1110303A (en) Methods and compositions for treating cancer
AU2003234570A1 (en) Tumor suppressor locus in prostate cancer